Core Viewpoint - The company has approved the use of its own funds to pay for part of the investment project costs, which will later be replaced with raised funds, ensuring compliance with regulations and maintaining operational efficiency [23][29][31]. Group 1: Company Overview - The company is named Haishike Pharmaceutical Group Co., Ltd. and is publicly traded with the stock code 002653 [10]. - The company held its fifth board meeting on August 22, 2025, where all directors attended and approved the half-year report [2][5]. Group 2: Financial Data - The company raised a total of RMB 800 million through a non-public stock issuance, with a net amount of RMB 790.87 million after deducting issuance costs [11][23]. - The company has established a special account for the management of raised funds, ensuring compliance with regulatory requirements [12][23]. Group 3: Fund Usage - The company plans to use surplus funds from previous projects for new initiatives, including RMB 16.42 million for working capital and RMB 53.02 million for clinical research projects [25]. - The company has not changed the implementation location or method for any investment projects during the reporting period [14]. Group 4: Fund Management - The company has implemented a cash management strategy for temporarily idle raised funds, generating a cash return of RMB 1.39 million during the reporting period [15]. - The company has established a process for replacing its own funds with raised funds within six months, ensuring that the funds are used effectively [27][28]. Group 5: Compliance and Oversight - The board of directors has ensured that the use of self-funds for project payments complies with relevant regulations and does not affect the project's implementation [29][31]. - The company has received no negative feedback from its sponsor regarding the fund management practices [31].

中信证券股份有限公司 经中国证券监督管理委员会《关于核准海思科医药集团股份有限公司非公开 发行股票的批复》（证监许可〔2022〕869 号）核准，公司于 2023 年 2 月 10 日 非公开发行人民币普通股（A 股）股票 40,000,000 股，发行价格为 20.00 元/股， 募 集 资 金 总 额 为 人 民 币 800,000,000.00 元 ， 扣 除 各 项 发 行 费 用 人 民 币 上述募集资金到位情况已经信永中和会计师事务所（特殊普通合伙）审验，于 募集资金验资报告》（XYZH/2022CDAA5B0008）。公司开立了募集资金专项账户， 对上述募集资金进行专户存储，并与保荐机构、存放募集资金的商业银行签署了 募集资金监管协议。 二、募投项目情况 鉴于公司 2020 年度非公开发行股票募集资金投资项目中的新药研发项目均 已取得药品注册证书/补充申请批准通知书且需支付的部分合同尾款也已基本支 付完毕，补充流动资金及偿还银行贷款也已实施完毕，公司决定将 2020 年度非 公开发行股票募集资金投资项目予以整体结项。公司于 2025 年 1 月 3 日召开第 五届董事会第二十一次会议、第五届监事 ...